Clinical Trial for the Safety and Efficacy of CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma
Latest Information Update: 21 Dec 2023
At a glance
- Drugs Anti-CD19 chimeric-antigen-receptor-T-cell-therapy-Yake-Biotechnology (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 21 Dec 2023 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
- 12 Dec 2023 Status changed from not yet recruiting to recruiting.
- 17 Dec 2020 New trial record